NSE / BSEHealthcare
β‚Ή1135.65-15.25-1.33%
P/E18.4Mkt Capβ‚Ή99.42 K CrEV/EBITDA14.3

Dr. Reddy's Laboratories Ltd.

P/E18.4Mkt Capβ‚Ή99.42 K CrEV/EBITDA14.3
Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–Ό 11.73% over 1Y
Monthly Returns

Historically, Jun has averaged the highest return (+5.7%); Jan the lowest (-4.2%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-4.1%Negative MonthJan 2026: -4.14%+5.6%Positive MonthFeb 2026: +5.65%-2.5%Negative MonthMar 2026: -2.53%+5.4%Positive MonthApr 2026: +5.44%-1.2%Neutral MonthMay 2026: -1.20%+3.8%Positive MonthJun 2026: +3.81%-16.3%*Negative MonthJul 2026: -16.30%β€”β€”β€”β€”β€”
2025-12.3%Negative MonthJan 2025: -12.29%-8.2%Negative MonthFeb 2025: -8.21%+2.4%Positive MonthMar 2025: +2.36%+3.4%Positive MonthApr 2025: +3.40%+5.8%Positive MonthMay 2025: +5.81%+2.6%Positive MonthJun 2025: +2.55%-1.0%Neutral MonthJul 2025: -1.00%-0.6%Neutral MonthAug 2025: -0.62%-3.1%Negative MonthSep 2025: -3.11%-2.1%Negative MonthOct 2025: -2.12%+5.0%Positive MonthNov 2025: +5.04%+1.0%Neutral MonthDec 2025: +1.03%
2024+5.6%Positive MonthJan 2024: +5.58%+4.9%Positive MonthFeb 2024: +4.88%-4.1%Negative MonthMar 2024: -4.13%+0.8%Neutral MonthApr 2024: +0.81%-6.7%Negative MonthMay 2024: -6.73%+10.7%Positive MonthJun 2024: +10.68%+5.4%Positive MonthJul 2024: +5.36%+4.2%Positive MonthAug 2024: +4.15%-3.9%Negative MonthSep 2024: -3.86%-5.7%Negative MonthOct 2024: -5.72%-5.6%Negative MonthNov 2024: -5.64%+15.5%Positive MonthDec 2024: +15.46%
2023+2.1%Positive MonthJan 2023: +2.12%-0.3%Neutral MonthFeb 2023: -0.29%+7.2%Positive MonthMar 2023: +7.20%+6.6%Positive MonthApr 2023: +6.60%-8.6%Negative MonthMay 2023: -8.58%+14.5%Positive MonthJun 2023: +14.48%+9.5%Positive MonthJul 2023: +9.51%-0.5%Neutral MonthAug 2023: -0.54%-0.5%Neutral MonthSep 2023: -0.52%-4.0%Negative MonthOct 2023: -4.02%+7.9%Positive MonthNov 2023: +7.94%+0.2%Neutral MonthDec 2023: +0.18%
2022-12.3%Negative MonthJan 2022: -12.31%-5.6%Negative MonthFeb 2022: -5.60%+6.0%Positive MonthMar 2022: +5.97%-4.0%Negative MonthApr 2022: -3.96%+5.7%Positive MonthMay 2022: +5.67%+0.7%Neutral MonthJun 2022: +0.70%-7.0%Negative MonthJul 2022: -7.04%+3.8%Positive MonthAug 2022: +3.77%+2.1%Positive MonthSep 2022: +2.11%+2.2%Positive MonthOct 2022: +2.25%+1.2%Neutral MonthNov 2022: +1.23%-5.6%Negative MonthDec 2022: -5.61%
2021β€”β€”β€”β€”β€”+2.1%Positive MonthJun 2021: +2.12%-13.1%Negative MonthJul 2021: -13.06%-0.2%Neutral MonthAug 2021: -0.22%+3.9%Positive MonthSep 2021: +3.89%-4.4%Negative MonthOct 2021: -4.41%+0.2%Neutral MonthNov 2021: +0.24%+4.9%Positive MonthDec 2021: +4.86%
AvgΒ±SD-4.2%Β±7.3%-0.7%Β±5.5%+1.8%Β±4.5%+2.5%Β±3.8%-1.0%Β±6.0%+5.7%Β±5.1%-3.8%Β±9.3%+1.3%Β±2.2%-0.3%Β±3.0%-2.8%Β±2.8%+1.8%Β±4.6%+3.2%Β±7.0%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 0.893x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή23.11 K Crβ–² 18.6%
EBITDA Growthβ€”
Net Profitβ‚Ή5.35 K Crβ–² 23.2%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–² 32.6%
Revenue CAGR 5Y10.5%
EBITDA CAGR 5Y13.4%
Net Profit CAGR 5Y8.1%
NP Growth 1Y23.2%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή23.11 K Crβ€”β‚Ή5.35 K Crβ€”β€”18.5%18.6%23.2%
Mar 2024β‚Ή19.48 K Crβ€”β‚Ή4.34 K Crβ€”β€”17.9%14.9%66.2%
Mar 2023β‚Ή16.96 K Crβ€”β‚Ή2.61 K Crβ€”β€”12.8%17.8%61.0%
Mar 2022β‚Ή14.40 K Crβ€”β‚Ή1.62 K Crβ€”β€”8.9%7.9%-25.8%
Mar 2021β‚Ή13.35 K Crβ€”β‚Ή2.19 K Crβ€”β€”12.9%12.6%-25.6%
Mar 2020β‚Ή11.85 K Crβ€”β‚Ή2.94 K Crβ€”β€”19.3%11.5%130.1%
Mar 2019β‚Ή10.63 K Crβ€”β‚Ή1.28 K Crβ€”β€”10.1%13.5%125.2%
Mar 2018β‚Ή9.36 K Crβ€”β‚Ή567.00 Crβ€”β€”4.8%-3.7%-59.0%
Mar 2017β‚Ή9.72 K Crβ€”β‚Ή1.38 K Crβ€”β€”11.9%-5.6%0.7%
Mar 2016β‚Ή10.29 K Crβ€”β‚Ή1.37 K Crβ€”β€”11.4%2.8%-18.2%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales9,72810,01110,2929,7209,35910,62611,85013,34914,40516,96219,48423,11523,006
Total Expenses6,9507,6088,2197,8997,9908,2908,96710,21211,80312,72413,55715,69116,053
EBIT / Operating Profit2,7782,4032,0731,8201,3702,3362,8833,1372,6024,2385,9267,4256,953
OPM %29%24%20%19%15%22%24%24%18%25%30%32%30%
Other Income1352113175161642027308014745688629611,412
Finance Costs7864645763574847381722110127
Depreciation & Amortisation3804906507357747817898358149239761,0391,104
Profit Before Tax2,4542,0601,6771,5446971,7012,7763,0562,2243,8665,7917,2367,134
Tax %21%18%18%10%19%25%-6%28%27%32%25%26%-
Net Profit / PAT1,9331,6791,3741,3845671,2772,9382,1861,6232,6134,3425,3495,399
EPS (β‚Ή)22.7319.7116.1116.706.8315.3835.3626.2919.5131.3852.0664.1164.69
Dividend Payout %16%20%25%24%59%26%14%19%31%26%15%12%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Dr. Reddy's Laboratories Ltd.this co.β‚Ή99.42 K Crβ‚Ή23.11 K Cr18.403.1514.3418.6%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Dr. Reddy's Laboratories Ltd. and the metrics that matter.

Browse the full Equiscale Academy